Log in

NASDAQ:XBITXBiotech Stock Price, Forecast & News

+0.35 (+2.43 %)
(As of 05/26/2020 04:00 PM ET)
Today's Range
Now: $14.77
50-Day Range
MA: $14.21
52-Week Range
Now: $14.77
Volume130,505 shs
Average Volume639,783 shs
Market Capitalization$426.14 million
P/E RatioN/A
Dividend YieldN/A
XBiotech Inc., a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is bermekimab, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection and influenza diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.
Read More
XBiotech logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.47 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:XBIT



Sales & Book Value

Annual SalesN/A
Cash Flow$16.60 per share
Book Value$18.20 per share


Net Income$668.63 million


Market Cap$426.14 million
Next Earnings Date5/28/2020 (Estimated)

Receive XBIT News and Ratings via Email

Sign-up to receive the latest news and ratings for XBIT and its competitors with MarketBeat's FREE daily newsletter.

XBiotech (NASDAQ:XBIT) Frequently Asked Questions

How has XBiotech's stock been impacted by COVID-19 (Coronavirus)?

XBiotech's stock was trading at $10.72 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, XBIT stock has increased by 37.8% and is now trading at $14.77. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of XBiotech?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XBiotech in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for XBiotech.

When is XBiotech's next earnings date?

XBiotech is scheduled to release its next quarterly earnings announcement on Thursday, May 28th 2020. View our earnings forecast for XBiotech.

How were XBiotech's earnings last quarter?

XBiotech Inc (NASDAQ:XBIT) announced its quarterly earnings data on Tuesday, November, 12th. The biopharmaceutical company reported ($0.15) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.15). View XBiotech's earnings history.

What price target have analysts set for XBIT?

2 brokerages have issued 12-month price targets for XBiotech's shares. Their forecasts range from $18.00 to $28.00. On average, they anticipate XBiotech's share price to reach $23.00 in the next twelve months. This suggests a possible upside of 55.7% from the stock's current price. View analysts' price targets for XBiotech.

Has XBiotech been receiving favorable news coverage?

News headlines about XBIT stock have trended negative recently, InfoTrie reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. XBiotech earned a media sentiment score of -2.6 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 9.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. View the latest news aboutXBiotech.

Are investors shorting XBiotech?

XBiotech saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 2,220,000 shares, a drop of 7.5% from the April 30th total of 2,400,000 shares. Based on an average daily volume of 513,200 shares, the short-interest ratio is currently 4.3 days. Currently, 16.2% of the shares of the stock are sold short. View XBiotech's Current Options Chain.

Who are some of XBiotech's key competitors?

What other stocks do shareholders of XBiotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other XBiotech investors own include Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Cidara Therapeutics (CDTX), Micron Technology (MU), Novavax (NVAX), Ocular Therapeutix (OCUL), Sanofi (SNY), Crispr Therapeutics (CRSP), SCYNEXIS (SCYX) and VBI Vaccines (VBIV).

Who are XBiotech's key executives?

XBiotech's management team includes the following people:
  • Mr. John Simard, Founder, Pres, CEO & Chairman (Age 57)
  • Dr. Sushma Shivaswamy, Chief Scientific Officer (Age 41)
  • Ms. Queena Han B.A., CPA, C.G.A., VP of Fin. & HR and Sec. (Age 52)
  • Mr. Benjamín Guzmán, Sr. VP of Corp. Strategy & Fin. (Age 63)
  • Dr. William Levis, Interim Medical Director and Member of Scientific Advisory Board

When did XBiotech IPO?

(XBIT) raised $76 million in an IPO on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $18.00-$20.00 per share. WR Hambrecht + Co acted as the underwriter for the IPO.

What is XBiotech's stock symbol?

XBiotech trades on the NASDAQ under the ticker symbol "XBIT."

Who are XBiotech's major shareholders?

XBiotech's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.47%), Geode Capital Management LLC (0.96%), State Street Corp (0.92%), Jane Street Group LLC (0.49%), Russell Investments Group Ltd. (0.36%) and Nuveen Asset Management LLC (0.21%). Company insiders that own XBiotech stock include Fondation Rennes, Street Financial SA Bay, W Thorpe Mckenzie and W Thorpe Mckenzie. View institutional ownership trends for XBiotech.

Which major investors are selling XBiotech stock?

XBIT stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Geode Capital Management LLC, Alps Advisors Inc., Squarepoint Ops LLC, Bank of New York Mellon Corp, Morgan Stanley, and Nuveen Asset Management LLC. View insider buying and selling activity for XBiotech.

Which major investors are buying XBiotech stock?

XBIT stock was purchased by a variety of institutional investors in the last quarter, including Jane Street Group LLC, Balyasny Asset Management LLC, Russell Investments Group Ltd., Paloma Partners Management Co, Alliancebernstein L.P., AQR Capital Management LLC, BNP Paribas Arbitrage SA, and Meeder Asset Management Inc.. Company insiders that have bought XBiotech stock in the last two years include Fondation Rennes, and W Thorpe Mckenzie. View insider buying and selling activity for XBiotech.

How do I buy shares of XBiotech?

Shares of XBIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is XBiotech's stock price today?

One share of XBIT stock can currently be purchased for approximately $14.77.

How big of a company is XBiotech?

XBiotech has a market capitalization of $426.14 million. XBiotech employs 56 workers across the globe.

What is XBiotech's official website?

The official website for XBiotech is www.xbiotech.com.

How can I contact XBiotech?

XBiotech's mailing address is 5217 Winnebago Ln, AUSTIN TX, 78744. The biopharmaceutical company can be reached via phone at 512-386-2900 or via email at [email protected]

This page was last updated on 5/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.